About Piqray (Alpelisib)

Alpelisib (Piqray, Alpelisib), a targeted drug developed by the Swiss company Novartis, has brought new hope to the treatment of breast cancer. The birth of this drug is based on in-depth research and unremitting exploration of current cancer treatments, providing an effective treatment option for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA gene mutations, and advanced or metastatic breast cancer.

Apelix has a unique mechanism of action. It precisely interferes with the growth and spread of breast cancer cells by inhibiting thePI3K/AKT signaling pathway. This innovative treatment strategy enabled Apelix to demonstrate significant efficacy in clinical trials. When used in combination with fulvestrant, apelvis can significantly improve patients' progression-free survival and reduce the risk of disease progression, bringing new hope to breast cancer patients.

Although Apelix has achieved remarkable results in efficacy, patients still need to pay attention to its possible side effects during use. Nausea, vomiting, tiredness, change in food taste, loss of appetite, weight loss, etc. are common side effects, while severe diarrhea, high blood sugar, etc. are relatively rare. Therefore, when using Apelvis, patients should do so under the guidance of a doctor and regularly monitor their physical condition in order to promptly detect and deal with possible adverse reactions.

Currently, Apelvis is available as an oral tablet. The recommended dose is300 mg (two 150 mg tablets), taken orally once daily with food. For adverse reactions, interrupt the dose, reduce the dose or discontinue the drug under the guidance of a doctor. If you have other medication problems, please communicate with your doctor in time.

It is understood that Apelvis has not yet been launched in China, but patients can purchase it through regular overseas channels. In countries such as India and Laos, both original and generic versions are available. Patients can choose the appropriate version for use according to their own conditions, but they must ensure that the purchasing channel is formal and reliable to ensure the quality and efficacy of the drug.

In short, Apelvis, as an innovative targeted drug, has brought new breakthroughs in the treatment of breast cancer. However, due to its nature as a prescription drug, patients are advised to use it under the guidance of a professional physician to ensure the safety and effectiveness of treatment.